News | October 25, 2021
Biocon reports a consolidated net profit of Rs. 138.3 crore in Q2FY22
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
The Research Services and Biosimilars business segments reported a growth of 17% and 10%, respectively
Key takeaways of recent quarter & conference call highlights
The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
The company’s wide therapeutic portfolio helped to sustain growth despite changing market demand
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
Ivenix selected Tritan MXF for the pump exterior because of its excellent chemical resistance and durability in the face of the aggressive disinfection protocols needed to prevent the spread of healthcare-associated infections
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Second interchangeable biosimilar product approved by agency
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
The Amplitude Solution gives laboratories the ability to scale Covid-19 PCR testing and process up to 8,000 samples a day
Subscribe To Our Newsletter & Stay Updated
